These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21862943)

  • 1. Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography.
    Contractor KB; Kenny LM; Stebbing J; Challapalli A; Al-Nahhas A; Palmieri C; Shousha S; Lewis JS; Hogben K; De Nguyen Q; Coombes RC; Aboagye EO
    Nucl Med Commun; 2011 Nov; 32(11):997-1004. PubMed ID: 21862943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer.
    Challapalli A; Barwick T; Tomasi G; O' Doherty M; Contractor K; Stewart S; Al-Nahhas A; Behan K; Coombes C; Aboagye EO; Mangar S
    Nucl Med Commun; 2014 Jan; 35(1):20-9. PubMed ID: 24201549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET.
    Kameyama R; Yamamoto Y; Izuishi K; Takebayashi R; Hagiike M; Murota M; Kaji M; Haba R; Nishiyama Y
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):382-8. PubMed ID: 18985344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3'-Deoxy-3'-¹⁸F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer.
    Challapalli A; Barwick T; Pearson RA; Merchant S; Mauri F; Howell EC; Sumpter K; Maxwell RJ; Aboagye EO; Sharma R
    Eur J Nucl Med Mol Imaging; 2015 May; 42(6):831-40. PubMed ID: 25673055
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Romine PE; Peterson LM; Kurland BF; Byrd DW; Novakova-Jiresova A; Muzi M; Specht JM; Doot RK; Link JM; Krohn KA; Kinahan PE; Mankoff DA; Linden HM
    Breast Cancer Res; 2021 Aug; 23(1):88. PubMed ID: 34425871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [¹⁸F]fluorothymidine-positron emission tomography in patients with locally advanced breast cancer under bevacizumab treatment: usefulness of different quantitative methods of tumor proliferation.
    Marti-Climent JM; Dominguez-Prado I; Garcia-Velloso MJ; Boni V; Peñuelas I; Toledo I; Richter JA
    Rev Esp Med Nucl Imagen Mol; 2014; 33(5):280-5. PubMed ID: 25066253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [11C]choline positron emission tomography in estrogen receptor-positive breast cancer.
    Contractor KB; Kenny LM; Stebbing J; Al-Nahhas A; Palmieri C; Sinnett D; Lewis JS; Hogben K; Osman S; Shousha S; Lowdell C; Coombes RC; Aboagye EO
    Clin Cancer Res; 2009 Sep; 15(17):5503-10. PubMed ID: 19706823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of
    Mori M; Fujioka T; Ichikawa R; Inomata R; Katsuta L; Yashima Y; Yamaga E; Tsuchiya J; Hayashi K; Kumaki Y; Oda G; Nakagawa T; Onishi I; Kubota K; Tateishi U
    Tomography; 2022 Oct; 8(5):2533-2546. PubMed ID: 36287810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
    Yamamoto Y; Nishiyama Y; Ishikawa S; Nakano J; Chang SS; Bandoh S; Kanaji N; Haba R; Kushida Y; Ohkawa M
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1610-6. PubMed ID: 17530250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy.
    Contractor K; Challapalli A; Tomasi G; Rosso L; Wasan H; Stebbing J; Kenny L; Mangar S; Riddle P; Palmieri C; Al-Nahhas A; Sharma R; Turkheimer F; Coombes RC; Aboagye E
    Phys Med Biol; 2012 Jun; 57(11):3419-33. PubMed ID: 22572708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.
    Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA
    Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
    Kenny L; Coombes RC; Vigushin DM; Al-Nahhas A; Shousha S; Aboagye EO
    Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1339-47. PubMed ID: 17333178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
    Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.
    Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH
    Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response.
    Benz MR; Czernin J; Allen-Auerbach MS; Dry SM; Sutthiruangwong P; Spick C; Radu C; Weber WA; Tap WD; Eilber FC
    Cancer; 2012 Jun; 118(12):3135-44. PubMed ID: 22020872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of 11C-choline PET/CT for lung cancer diagnosis and the relation between choline metabolism and proliferation of cancer cells.
    Li M; Peng Z; Liu Q; Sun J; Yao S; Liu Q
    Oncol Rep; 2013 Jan; 29(1):205-11. PubMed ID: 23124523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods.
    Kenny LM; Vigushin DM; Al-Nahhas A; Osman S; Luthra SK; Shousha S; Coombes RC; Aboagye EO
    Cancer Res; 2005 Nov; 65(21):10104-12. PubMed ID: 16267037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study.
    Smyczek-Gargya B; Fersis N; Dittmann H; Vogel U; Reischl G; Machulla HJ; Wallwiener D; Bares R; Dohmen BM
    Eur J Nucl Med Mol Imaging; 2004 May; 31(5):720-4. PubMed ID: 14991243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.